Slide 1: SUSTOL Approval
SUSTOL Approval August 10, 2016
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on managements expectations and assumptions as of the date of this presentation, and i
Slide 3: SUSTOL Now approved by U.S. FDA; U.S. Commercial Launch Planned For Q4 2016
SUSTOL Now approved by U.S. FDA U.S. Commercial Launch Planned For Q4 2016
Slide 4: Preventing CINV throughout both acute and delayed phases remains a significant unmet need
Preventing CINV throughout both acute and delayed phases remains a significant unmet need Patients identified CINV as the side effect of% of emetogenic chemotherapy patients with chemotherapy they most wanted to avoid breakthrough CINV despite prophylaxis Physician perception Least acceptable 50% 50
Slide 5: SUSTOL Indication
SUSTOL Indication SUSTOL is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy
Slide 6: AC-based regimens are classified as highly emetogenic by national clinical practice guidelines
AC-based regimens are classified as highly emetogenic by national clinical practice guidelines Highly Emetogenic Chemotherapy AC combination chemotherapy* Dacarbazine Carmustine >250 mg/m2 Doxorubicin >60 mg/m2 Cisplatin Epirubicin >90 mg/m2 NCCN Cyclophosphamide >1,500 mg/m2 Ifosfamide
Slide 7: The branded 5-HT3 market (Aloxi) consists of ~2.5 million units
The branded 5-HT3 market (Aloxi) consists of ~2.5 million units Injectable 5-HT3 Receptor Antagonists for the Prevention of CINV Number of Vials Sold in the U.S. by Quarter 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 — Q1’13 Q2’13 Q3’13 Q4’13 Q1’14 Q2’14 Q3’14 Q4’14 Q1’15 Q2’15 Q
Slide 8: 93% of palonosetron units are used outside of cisplatin
93% of palonosetron units are used outside of cisplatin Total U.S. palonosetron Units (2015) 3.0 By Chemo Regimen 2.5 0.18 (Millions) 2.0 Cisplatin 1.5 Other Chemotherapy Units 2.35 1.0 0.5 0.0 Source: Intrinsiq 2013 (for Aloxi units); Symphony 2015 (for proportion of chemo that is cisplatin) 8
Slide 9: Our target market can be reached by a small but focused commercial team
Our target market can be reached by a small but focused commercial team Commercial launch to be highly-targeted with two key phases Phase 1 Targets Highly-concentrated 700K branded units (50%) in 70 practices (533 sites) Phase 1 Targets Value clinical advances over 1st (First 12-18 months) generatio
Slide 10: Heron's commercial plans will address potential launch barriers for providers, patients, and payers
Herons commercial plans will address potential launch barriers for providers, patients, and payers Objectives Action Plan First and only 5-HT3 with advanced, extended-release technology Establish SUSTOL and 5-day CINV prevention in MEC and AC-based HEC regimens1 clinical value & address objectio
Slide 11: U.S. commercial organization is poised for launch
U.S. commercial organization is poised for launch U.S. Commercial Organization Marketing Sales Phase 1 Targets Market Access(First 12-18 months) GPO Account Team ~1.4MM Units Payer Account Team MSLs / Nurse Educators Source: Symphony SNR data 2015 11
Slide 12: SUSTOL Now Approved
SUSTOL Now Approved Despite advances in the management of CINV, up to half of patients receiving chemotherapy can still experience CINV, with delayed CINV being particularly challenging to control, commented Ralph V. Boccia, MD, FACP, Medical Director, Center for Cancer and Blood Disorders. In our e